Delve and Collaborators Discuss the Development of Delve Neuro at AGBT 2024
Delve and Collaborators from Broad Clinical Labs present at AGBT on the Development of a Rapid and Cost-Effective NGS-based Assay for the Clinical Diagnosis of Meningitis and Encephalitis.
Delve Neuro provides pathogen-agnostic and unbiased detection of neuro-infectious pathogens in cerebrospinal fluid (CSF) in one shot.
- Samples the entire metagenomic content – DNA and RNA – within a patient sample.
- Uses a proprietary mNGS bioinformatic pipeline to rapidly analyze millions of sequences.
- Rapidly and accurately identifies bacterial, viral, fungal, and parasitic species.
As exclusive licensee of University of California San Francisco’s (UCSF) metagenomic sequencing (mNGS) technology, Delve Bio leverages mNGS to empower labs and clinicians with the results they need to diagnose routine and rare infectious diseases.
Meet the Delve Team
Brad Murray, MBA
Founder & CEO
Emily Crawford, PhD
Head of R&D
Steve Miller, MD, PhD
Chief Medical Officer
Chief Commercial Officer
Coren Milbury, PhD
VP of Product Development and Leadership
Director of Software Engineering
Amy Wong, PhD
Senior Director of Marketing and Business Development
Brian O’Donovan, PhD
Head of Bioinformatics
Pardis Sabeti, MD, PhD
Professor, Harvard University
Institute Member, Broad Institute
Joe DeRisi, PhD
Professor, University of California San Francisco
President, Chan Zuckerberg Biohub
Matthew Meyerson, MD, PhD
Director, Center for Cancer Genomics, Dana-Farber Cancer Institute
Professor of Genetics and Medicine, Harvard Medical School
Institute Member, Cancer Program, Broad Institute
Charles Chiu, MD, PhD
Professor, Laboratory Medicine and Medicine / Infectious Diseases, University of California, San Francisco
Associate Director, UCSF Clinical Microbiology Laboratory
Investigator, Chan-Zuckerberg Biohub